The U.S. Food and Drug Administration (USFDA) has flagged data integrity, manufacturing and maintenance-related lapses at one of Dabur India’s facilities following an inspection conducted earlier this year. The findings were issued after the regulator inspected the company’s facility in Dadra and Nagar Haveli in January. The inspection report cited risks of microbiological contamination, alleged falsification of certain manufacturing records, and deficiencies in maintenance and quality review processes. Dabur later said it is actively engaging with the USFDA, has submitted a corrective and preventive action plan, and that the observations relate only to a small part of its Silvassa manufacturing facility.
Key Takeaways: US FDA Inspection of Dabur India Facility
- USFDA identified data integrity, manufacturing and maintenance-related lapses at a Dabur India plant.
- The inspection was conducted in January at the company’s facility in Dadra and Nagar Haveli.
- Some units were found to pose risks of microbiological contamination.
- The report cited alleged falsification of critical manufacturing records.
- A live bird, bird droppings and unidentified black substances were observed in warehouse areas.
- Dabur said the observations relate only to a small part of its Silvassa plant.
- The company stated that the plant remains operational.
- Dabur said it has submitted a corrective and preventive action plan to the USFDA.
- The company maintained that there is no impact on its financials, operations or other business activities.
USFDA Inspection Raises Concerns at Dabur India Facility
The U.S. Food and Drug Administration flagged data integrity, manufacturing and maintenance lapses at one of Dabur India’s plants following an inspection earlier this year, according to an inspection report. The findings were issued after the FDA inspected the company’s facility in Dadra and Nagar Haveli in January.
Dabur is one of India’s oldest and largest consumer goods companies and describes itself as one of the world’s largest suppliers of Ayurvedic products with a legacy of over 140 years. The company sells a range of over-the-counter and consumer health products in the United States, including cough and cold rubs, antifungal creams, pain relief gels and oral care products.
According to the inspection findings, some units in the facility posed risks of microbiological contamination.
Also Read: Poison on Your Plate: The Dark Side of Food Adulteration
Key Findings Highlighted in the Inspection Report
The inspection report identified several observations related to manufacturing practices, facility conditions and record-keeping procedures.
| Inspection Area | Observation |
| Data Integrity | Critical manufacturing records were allegedly falsified |
| Manufacturing Practices | Equipment designated for specific products was reportedly used for multiple products |
| Contamination Risk | Some units posed microbiological contamination risks |
| Warehouse Conditions | Live bird and bird droppings found in raw material warehouse |
| Storage Areas | Unidentified black substance covered more than 25% of certain ceiling surfaces |
| Quality Oversight | Production and quality records were not reviewed before release of batches |
| Maintenance | Deficiencies cited in equipment cleaning and maintenance procedures |
According to the report, certain critical manufacturing records were falsified to conceal that equipment designated for specific products had been used for multiple other products.
Contamination and Facility Condition Observations
The FDA findings included observations related to facility hygiene and contamination risks.
A live bird and bird droppings were found in the raw material warehouse, approximately 30 feet from packaging materials. The inspection report also stated that an apparent unidentified black substance covered more than 25% of ceiling surfaces in both the raw material warehouse and the finished drug product storage warehouse.
The report, which was made public earlier this week, stated that some units at the facility posed risks of microbiological contamination.
The FDA inspector also questioned the reliability of testing at the plant. According to the findings, microbiology test results were reported as being within limits, yet significant contamination was observed in multiple samples during the inspection.
Questions Raised Over Quality and Compliance Processes
Beyond contamination concerns, the inspection report also highlighted issues related to compliance oversight.
According to the report, management had not reviewed drug production and quality records to determine compliance with regulatory requirements before batches were released to the market.
The report further cited deficiencies in equipment cleaning and maintenance procedures.
Also Read: Why Does Your Child Refuse Food? Handling Picky Eaters Calmly
These findings emerged amid heightened regulatory scrutiny of Indian drugmakers over quality controls for medicines and health products exported to the United States, which remains their largest overseas market.
Form 483 and Regulatory Follow-Up
The report noted that following a Form 483, which is issued after a U.S. FDA inspection, companies usually respond to the regulator with corrective steps taken to address the concerns identified during the inspection.
Reuters reported that the FDA observations were issued after the January inspection of the facility in Dadra and Nagar Haveli.
At the time of the Reuters report, Dabur did not immediately respond to a request for comment regarding the inspection findings.
Dabur Responds to USFDA Observations
Subsequently, Dabur issued an exchange filing addressing the observations.
The company said the observations relate only to a small part of its manufacturing plant at Silvassa in Dadra and Nagar Haveli and that the unit contributes insignificant revenue to the company.
“The aforesaid plant continues to be operational,” Dabur said.
The company stated that it is actively engaged with the USFDA regarding the audit findings and has prepared a corrective and preventive action plan to address the concerns raised.
According to Dabur, the action plan has already been shared with the USFDA and updates on progress are being provided regularly.
The company further stated that it continues to implement strong controls to ensure that its quality systems are not compromised and remains committed to maintaining high standards of product quality across its manufacturing operations.
Dabur also said there is no impact on its financials, operations or any other business activities due to the observations.
Market Reaction Following the Developments
Dabur India shares declined more than 4% on Monday after the developments came into focus. However, shares of the company later settled more than 4% higher at Rs 425.05 per share on the NSE.
The market reaction followed reports regarding the USFDA observations and the company’s subsequent clarification regarding the operational status of the facility and its engagement with the regulator.
Regulatory Review and Corrective Measures Continue
The USFDA findings and Dabur’s response remain central to developments surrounding the facility in Dadra and Nagar Haveli. While the inspection report highlighted concerns ranging from contamination risks and record-keeping practices to maintenance procedures, the company has stated that the observations affect only a small part of its Silvassa manufacturing plant. Dabur says the facility continues to operate, corrective measures have been shared with the regulator, and there has been no impact on its business operations, financial performance or other activities.
True Knowledge Promotes Integrity
The observations highlighted in the inspection report draw attention to the importance of honesty, accountability and discipline in professional and personal conduct. Issues related to record-keeping, quality controls and compliance often reinforce the broader principle that transparency remains essential in every field of work.
According to Tatvadarshi Sant Rampal Ji Maharaj, a person without true spiritual knowledge may become influenced by ignorance and may deviate from the path of truth. He explains that true Knowledge encourages ethical conduct, responsibility and sincerity in daily life, values that support trust and integrity in society.
For more information visit our:
Website: www.jagatgururampalji.org
YouTube: Sant Rampal Ji Maharaj
Facebook: Spiritual Leader Saint Rampal Ji
X (Twitter): @SaintRampalJiM
FAQs on US FDA Dabur India Plant Inspection
1. What did the USFDA find at the Dabur India facility?
The USFDA identified data integrity, manufacturing and maintenance-related lapses, along with microbiological contamination risks and quality control concerns.
2. Where is the facility inspected by the USFDA located?
The inspection was conducted at Dabur India’s facility in Dadra and Nagar Haveli in January.
3. What did the report say about manufacturing records?
The report stated that certain critical manufacturing records were falsified to conceal equipment usage across multiple products.
4. How has Dabur responded to the observations?
Dabur said it submitted a corrective and preventive action plan and is providing regular updates to the USFDA.
5. Has Dabur reported any business impact from the observations?
No. The company stated that there is no impact on its financials, operations or any other business activities.
